|
|
Deň zápisu
|
| 4919 |
Dostarlimab (Jemperli®) – Résumé des caractéristiques du produits |
03/03/2025 |
| 4917 |
A Physicochemical Stability Study of Pembrolizumab Vial Leftovers: Let Us Stop Pouring Good Money Down the Drain. Pharmacy |
18/02/2025 |
| 4914 |
In‐Use Physicochemical Stability of Sandoz Rituximab Biosimilar in 0.9% Sodium Chloride Solution After Prolonged Storage at Room Temperature Conditions. Drugs R D |
02/02/2025 |
| 4911 |
Glofitamab (Columvi®) - Résumé des caractéristiques du produit |
28/01/2025 |
| 4912 |
Tafasitamab (Minjuvi®) - Résumé des caractéristiques du produit |
28/01/2025 |
| 4913 |
Teclistamab (Tecvayli®) - Résumé des caractéristiques du produit |
28/01/2025 |
| 4904 |
Y-site simulation compatibility study of 10% calcium salts with various injectable solutions during toxicological resuscitation. EJHP |
15/01/2025 |
| 4905 |
Characterization of Liquid Dosage Forms of Atenolol and Enalapril Maleate for Oral and Enteral Feeding Administration Pharmaceuticals |
15/01/2025 |
| 4895 |
Real-World Nivolumab Wastage and Leftover Drug Stability Assessment to Facilitate Drug Vial for Cost Savings. JCO Oncology Practice |
07/01/2025 |
| 4891 |
Physicochemical and Biological Stability Assessment of SB11 (Ranibizumab Biosimilar) Under Ambient and In-Use Storage for Intravitreal Administration. Ophtalmol Ther |
06/01/2025 |
| 4892 |
Combined physicochemical and functional assessment of pertuzumab integrity supports extended in‐use stability. Arch Pharm |
06/01/2025 |
| 4888 |
Stabilité du propofol, du rocuronium, du phénobarbital et du magnésium injectables reconditionnés en seringue pour les trousses d’aide médicale à mourir. Pharmactuel |
01/01/2025 |
| 4887 |
IMJUDO (tremelimumab) 20 mg/mL concentrate for solution for infusion. Summary of Product Characteristics. Astra Zenaca AB |
14/12/2024 |
| 4886 |
Physicochemical and Microbiological Stability of Ursodiol Oral Compounded Suspensions. J Pediatr Pharmacol Ther |
11/12/2024 |
| 4884 |
Stability of Diluted Desmopressin Acetate Intranasal Solution at 0.01 mg/mL. Int J Pharm Compound |
06/12/2024 |
| 4883 |
Physicochemical I.Stability of Nab-Paclitaxel (Pazenir) Infusion Dispersions in Original Glass Vials and EVA Infusion Bags. Pharmaceutics |
27/11/2024 |
| 4878 |
Compatibility of Cetirizine Hydrochloride, Dutasteride, Hydrocortisone Acetate, Nicotinamide, Porgesterone, and Pyridoxine Hydrochloride in TrichoSol, A Natural Vehicle for Hair Solutions. Int J Pharm Compound |
08/11/2024 |
| 4879 |
Compatibility of Active Pharmaceutical Ingredients in Cleoderm: A Comprehensive Study for Enhanced Topical Dermatological Treatments. Int J Pharm Compound |
08/11/2024 |
| 4880 |
Stability of Allopurinol in Extemporaneously Compounded Oral Suspensions with Oral Mix and Oral Mix SF. Int J Pharm Compound |
08/11/2024 |
| 4867 |
Etude des compatibilités entre la nalbuphine et d'autres principes actifs pour optimiser leur administration en service de pédiatrie. CSH (SNPHPU) Congress sept 2024 |
17/10/2024 |
| 4868 |
Etude de la stabilité physico-chimique de solutions de 5-fluorouracile diluées en poches polyoléfine a des concentrations comprises entre 9 et 15 mg/ml. CSH (SNPHPU) Congress sept 2024 |
17/10/2024 |
| 4865 |
Cyclophosphamide REDDY PHARMA 2000 mg/4 ML, solution à diluer pour solution injectable/perfusion. - Résumé des caractéristiques du produit. Dr REDDY laboratoire |
01/10/2024 |
| 4863 |
Physical Compatibility Between Intravenous Magnesium Sulfate and Potassium or Sodium Phosphate in a Pediatric Intensive Care Unit. Hosp Pharm |
25/09/2024 |
| 4855 |
Physical compatibility of colistin with analgesics during simulated Y-site administration. Am J Hosp Pharm |
04/09/2024 |
| 4857 |
Physicochemical and Microbiological Stability of Compounded Clonidine Hydrochloride Oral iquid Dosage Forms in PCCA Base, SuspendIt®. Int J Pharm Compound |
04/09/2024 |
| 4858 |
Physical Compatibility of Intravenous Ondansetron Hydrochloride and Nafcillin Sodium. Int J Pharm Compound |
04/09/2024 |
| 4859 |
Physicochemical and Microbiological Stability of Compounded Bethanechol Chloride Oral Suspensions in PCCA Base, SuspendIt® Int J Pharm Compound |
04/09/2024 |
| 4862 |
Erwinase, 10,000 IU/vial, Powder for solution for injection/infusion - Summary of Product Characteristics Updated 04-Jul-2022. Porton Biopharma Limited |
04/09/2024 |
| 4852 |
KEYTRUDA 25 mg/mL solution à diluer pour perfusion. Résumé des caractéristiques du produit. Merck Sharp & Dohme B.V. |
25/08/2024 |
| 4849 |
Formulation and Stability of a 1% Clarithromycin-Based Topical Skin Cream: A New Option to Treat Buruli Ulcers? Pharmaceuticals |
22/08/2024 |
